Stock of the Day

July 15, 2022

Cogent Biosciences (COGT)

$35.00
+$0.33 (+1.0%)
Market Cap: $6.02B

About Cogent Biosciences

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Today's Trend

Cogent Biosciences, Inc. (NASDAQ:COGT) is trading higher as investors weigh a bullish “Buy” rating and $55 price target from HC Wainwright against modestly reduced near-term earnings forecasts. With the stock recently around $36.63, the target implies substantial potential upside.

  • HC Wainwright maintained its “Buy” rating and $55 price objective for COGT, signaling confidence in Cogent Biosciences’ longer-term growth prospects. HC Wainwright analyst coverage
  • The analyst expects losses to narrow significantly in 2027, forecasting quarterly EPS of $(0.50), $(0.38), $(0.26), and $(0.15), resulting in a full-year loss of $(1.28). The improving trajectory may support the stock’s valuation if Cogent’s pipeline advances as expected. Cogent Biosciences 2027 earnings estimates
  • HC Wainwright initiated its 2027 estimates, including a $(1.28) full-year EPS forecast. These projections provide new expectations for investors but do not represent a change to the company’s operating results. Cogent Biosciences analyst estimates
  • HC Wainwright reduced its 2026 EPS forecasts, lowering Q3 estimates to $(0.59) from $(0.56), Q4 estimates to $(0.62) from $(0.57), and full-year estimates to $(2.37) from $(2.21). The revisions indicate higher expected losses in the near term and could limit upside despite the bullish rating. Cogent Biosciences 2026 earnings estimate revisions
← Previous Stock of the DayNext Stock of the Day →

Recent News